DOCK (Dedicator of Cytokinesis) family of proteins, with a particular focus on DOCK 4. The DOCK family, which stands for the dedicator of cytokinesis, consists of guanine nucleotide exchange factors (GEFs) that play a crucial role in regulating intracellular signaling pathways. DOCK 4, as a member of this family, is implicated in the modulation of cellular processes such as cytoskeletal rearrangement, cell migration, and cell adhesion. The inhibitors designed for DOCK 4 act by disrupting the GEF activity of the protein, thereby influencing downstream signaling cascades.
DOCK 4 inhibitors are carefully crafted compounds designed to fit into the active site of the DOCK 4 protein, hindering its ability to catalyze the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on target small GTPases. This interference in the nucleotide exchange process serves as a molecular switch, modulating the activity of downstream signaling pathways that are intricately involved in cellular dynamics. By selectively targeting DOCK 4, these inhibitors have the potential to influence cellular processes related to cell motility, a characteristic that holds significance in various physiological and pathological contexts, including development, immune response, and cancer metastasis. The development of DOCK 4 inhibitors represents a nuanced approach to manipulating cellular signaling, shedding light on the intricate molecular mechanisms that govern cellular behavior.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K, which can indirectly inhibit DOCK4 by blocking phosphoinositide 3-kinase, part of the signaling pathway that DOCK4 is involved in. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src inhibitor. DOCK4 interacts with Src family kinases, and inhibition of these kinases can indirectly reduce DOCK4 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP 2 is a selective Src family kinase inhibitor. It can indirectly inhibit DOCK4 by blocking the activity of Src kinases. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can indirectly inhibit DOCK4 by limiting mTOR signaling, a pathway that DOCK4 can also influence. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an Akt inhibitor. By suppressing Akt, it can indirectly limit the activity of DOCK4. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a potent mTOR inhibitor that can indirectly inhibit DOCK4 by suppressing mTOR signaling. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is an Akt inhibitor. It can indirectly inhibit DOCK4 by limiting Akt-mediated signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective MEK inhibitor. It can indirectly inhibit DOCK4 by blocking the ERK pathway, which DOCK4 can utilize. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. It can indirectly inhibit DOCK4 by suppressing JNK signaling, a pathway that DOCK4 can influence. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. It can indirectly inhibit DOCK4 by limiting p38 MAPK signaling. | ||||||